Table 3.
Estimates of actual and potential lives saved from the deployment of CCP in Italy, year 2021.
| (a) Hospitalized Patients | |||
|---|---|---|---|
| Relative Risk Reduction (%) 1 | Untreated Mortality (%) 2 |
Lives Saved (n) | |
| Real-Life | Theoretical 3 | ||
| 13 | 25.4 | 223 | 7623 |
| 23 | 25.4 | 395 | 13,488 |
| 44 | 25.4 | 756 | 25,802 |
| (b) Outpatients | |||
|
Population Treated
with CCP (%) 4 |
Hospitalization Reduction (%) 5 | Hospitalization Avoided (n) |
Lives Saved
(n) |
| 15 | 30 | 10,389 | 2639 |
| 75 | 30 | 51,947 | 13,194 |
| 15 | 54 | 18,701 | 4750 |
| 75 | 54 | 93,504 | 23,750 |
| 15 | 80 | 27,705 | 7037 |
| 75 | 80 | 138,524 | 35,185 |
1 The 13% value comes from reference no. 6; the 23% value comes from reference no. 13 and the 44% value comes from reference no. 15. 2 The 25.4% value comes from reference no. 18. 3 Calculated if 100% of inpatients were transfused with CCP. 4 Percentage of use of 15% was estimated from the actual use of monoclonal antibodies during the pandemic, which was given to patients at high risk for hospitalization. The 75% estimate assumes a major national effort to deploy outpatient plasma. 5 The 30% value comes from reference no. 21; the 54% value comes from reference no. 21 and the 80% value comes from reference no. 7.